Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Recurrent and Refractory Solid Tumors
Interventions
DRUG

Lenvatinib

oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension

DRUG

Everolimus

2 mg, 3 mg, or 5 mg tablets for oral suspension

Trial Locations (50)

10032

Columbia University/Herbert Irving Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10595

New York Medical College, Valhalla

11040

Cohen Children's Medical Center, New Hyde Park

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

19803

Nemours/ Alfred I. duPont Hospital for Children, Wilmington

20010

Children's National Medical Center, Washington D.C.

21287

Johns Hopkins, Baltimore

23507

Children's Hospital of The King's Daughters, Norfolk

32610

University of Florida, Gainesville

33155

Nicklaus Children's Hospital, Miami

33908

Golisano Children's Hospital of Southwest Florida, Fort Myers

35233

Children's Hospital of Alabama, Birmingham

37232

Vanderbilt University Medical Center, Nashville

39216

University of Mississippi Medical Center, Jackson

40202

University of Louisville and Norton Children's Hospital, Louisville

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children - Indiana University, Indianapolis

48109

CS Mott Children's Hospital, Ann Arbor

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

61637

St Jude Midwest Affiliate, Peoria

64108

Children's Mercy Hospital and Clinics, Kansas City

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75390

The University of Texas Southwestern Medical Center, Dallas

76104

Cook Children's Medical Center, Fort Worth

77030

Texas Children's Hospital, Houston

78207

The Children's Hospital of San Antonio, San Antonio

78723

Dell Children's Medical Center of Central Texas, Austin

80045

Children's Hospital Colorado, Aurora

85016

Phoenix Children's Hospital, Phoenix

89135

Alliance for Childhood Diseases, Las Vegas

90027

Children's Hospital of Los Angeles, Los Angeles

Southern California Permanente Medical Group, Los Angeles

90806

Miller Children's and Women's Hospital, Long Beach

92350

Loma Linda University Medical Center, Loma Linda

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center at Mission Bay - Pediatric Oncology, San Francisco

94611

Kaiser Permenente, Oakland

96826

Kapi'olani Medical Center, Honolulu

97239

Oregon Health & Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

07960

Morristown Medical Center, Morristown

08901

Rutgers cancer Institute of NJ, New Brunswick

B3K 6R8

IWK Health Centre, Halifax

M5G 1X8

Hospital for Sick Children, Toronto

H4A3J1

Montreal Children's Hospital, Montreal

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT03245151 - Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors | Biotech Hunter | Biotech Hunter